This long-term follow-up study demonstrates that adjuvant treatment with 5-FU plus leucovorin given for 12 cycles is significantly more effective than 5-FU plus levamisole (Moertel scheme) in reducing tumor relapse and improving survival.

Dec 2, 2022 · Leucovorin improves the binding of 5FU to the enzymes in cancer cells. This allows the chemotherapy to stay inside the body for a longer time, giving it the opportunity to kill...

Feb 28, 2024 · Folinic acid, also known as 5-formyl tetrahydrofolic acid or leucovorin, treats various cancers when employed with 5-fluorouracil (5-FU). Additionally, leucovorin serves as an antidote to folic acid antagonists like methotrexate.

May 2, 2006 · Adjuvant postoperative treatment with 5-fluorouracil (5-FU) and leucovorin in curatively resected stage III colon cancer significantly reduces the risk of cancer recurrences and improves survival.

5-Fluorouracil (5-Fu) and leucovorin (LV) are often given in combination to treat colorectal cancer. 5-Fu/LV prevents cell proliferation by inhibiting thymidylate synthase, which catalyzes the conversion of deoxyuridine monophosphate to deoxythymidine monophosphate.

The combination of oral tegafur-uracil (UFT) with leucovorin (LV) is used to treat patients with stage II to III colon cancer based on the results of postoperative randomized studies in which UFT/LV treatment showed an equivalent efficacy to intravenous 5-FU plus LV therapy.

Recent laboratory preclinical results suggest that the major site of action of 5-fluorouracil when combined with 5-formyltetrahydrofolate (folinic acid, leucovorin) is thymidylate synthase resulting in pronounced and prolonged inhibition of DNA synthesis.

This long-term follow-up study demonstrates that adjuvant treatment with 5-FU plus leucovorin given for 12 cycles is significantly more effective than 5-FU plus levamisole (Moertel scheme) in reducing tumor relapse and improving survival. Key words: adjuvant chemotherapy, colon cancer, 5-fluorouracil, leucovorin, levamisole

The true clinical value of bolus 5-FU right before infusional regimens remains to be determined since no randomized trials have addressed this issue. This manuscript aims to review the history of 5-FU, its mechanism of action and the data exploring the role of bolus 5-FU.

Original references may be found at 5-FU & high-dose Leucovorin (Roswell Park regimen/HDLV) (adjuvant) & 5-FU & high-dose Leucovorin (Roswell Park regimen/HDLV) (metastatic) 8-week cycles x 3-4 cycles for adjuvant therapy; in metastatic settings, given until progression of disease or unacceptable toxicity. Hydration: